Audrey’s Life Science Meeting Picks for March 2010(March 14th Edition)

*********************************************************************

UCSC Extension Intensive Clinical Trials Course, March 15-19, 2010

Course: Clinical Trial Essentials: An Intensive CourseExpert instructional team:

R. MICHAEL CROMPTON, J.D., M.P.H. is a regulatory affairs professional with more than 20 years of experience in the medical device industry. He is currently the vice president of Regulatory and Clinical Affairs and Quality at Micrus Endovascular Corp.

JERRY GEORGETTE, RN, MSN, CCRC, is a study nurse coordinator at the VA Palo Alto HCS and is past president of the Northern California Chapter of the Association of Clinical Research Professionals (ACRP).

MICHAEL HUSTON, M.B.A., B.S., is president of Huston Associates, LLC, and has more than 20 years of experience in the life science industry, from basic research to strategic drug development.

JACQUIE MARDELL, B.A., has a broad background in planning, implementation and analyzing clinical trials, and has lead teams in the preparation and execution of clinical development plans in many therapeutic areas.

JEAN MASONEK, RN, B.S.N., B.A., is the senior manager of drug safety at a Bay Area Biopharmaceutical company.

FRANCES A. MCKENNEY, M.S., is director of GCP compliance at Affymax. Ms. McKenney has more than 20 years of experience in the pharmaceutical/biotechnology industry, working for both sponsor/manufacturers and a CRO.

TAMMY MORTON-TAYLOR, M.S., has 18 years of research experience, with more than 13 years devoted to coordinating, monitoring and managing clinical trials. Her most recent clinical research focus has been in the medical device industry, where she has worked with devices for cardiology, women's health and endocrinology.

AUDREY ERBES, Ph.D., a marketing and business development consultant, Principal of Erbes & Associates and www.audreysnetwork.com, has more than 30 years of experience in the global biopharmaceutical industry, including project team role as business interface with clinical development

SUSANNE PROKSCHA, B.S., has worked in clinical data management and data management systems for more than 20 years and is the author of Practical Guide to Clinical Data Management.

EDWARD ROZHON, Ph.D., is a global studies manager in the Pharmaceutical Development Organization at Genentech/Roche. Dr. Rozhon has 22 years of pharmaceutical experience in nonclinical and clinical areas of drug discovery and development.

G. PETER SHABE, M.S., is a biostatistician and president of Advance Research Associates, Inc., a contract research organization (CRO) providing data-management and biostatistical services to the medical-device, biotech and pharmaceutical industries.

Dates and Time: March 15-19, 2010, 8:30 am – 5:00 pmLocation: 2505 Augustine Drive, Santa Clara, CACost: $1,675.00 (Fee includes all course materials, continental breakfasts, daily snacks and a networking lunch on the first day.)

1 5/20/2023

For more information, please contact UCSC Extension's Applied and Natural Sciences Department at (408) 861-3860, or program@ucsc-extension.edu.

Course Description:Well-planned and well-executed clinical trials are the cornerstones of effective drug and medical device development. Offered in an accelerated format and taught by leaders in the biopharmaceutical industry, this course provides a unique opportunity for professionals from all disciplines to learn about the many facets of clinical trials--the complex process that ensures the safety and effectiveness of medical products. Participants leave the program with an appreciation of the drug and device development process; good clinical practice (GCP) and other regulations (ICH and FDA) that guide the conduct of trials and protect human volunteers; clinical trial phases and design strategies; the importance of informed consent and the role of the IRB; investigator selection and responsibilities; study site management and trial monitoring; statistical data analysis; and regulatory responsibilities and the role of the FDA. This course benefits anyone working in the biopharmaceutical and medical device industries and the biomedical community who is interfacing with or conducting clinical research, including new clinical research associates and study coordinators; medical directors, physicians, nurses, pharmacists, and other health professionals; biomedical scientists; statisticians and database administrators; and business professionals. A team of clinical research experts, including many instructors from the Clinical Trials Design and Management Certificate Program, will present the following topics: 

Overview of the Drug and Medical Device Development Processes Clinical Trial Design Applied Statistics in Clinical Trials for the Non-Statistician Regulation of Clinical Research (including GCP and ICH) Roles and Responsibilities of Key Clinical Research Players, including the

Investigator, the Sponsor, the Clinical Study Site and the FDA Institutional Review Board (IRB) Perspectives Monitoring Clinical Trials Clinical Data Management Clinical QA, Auditing and Compliance Safety Reporting The Business of Clinical Research

****************************************************************************************************************

FountainBlue Life Science Forum, Monday Evening, March 15, 2010

Topic: International Challenges and Opportunities for Life Science CompaniesFacilitator from Morrison Foerster to be confirmed Panelist William Goure, President and CEO, Acumen PharmaceuticalsPanelist Taylor Kilfoil, President and CEO, InClin, Inc.Panelist Evgeny Zaytsev, General Partner, Helix Ventures

Presenting Entrepreneurs to be confirmedDate & Time: Monday, March 15 from 5:30 - 7:30 p.m. Location: Morrison Foerster, 755 Page Mill Road, Palo AltoCost: $21 members, $32 partners, $42 general

On-Site Registration is $42 for members, $52 for nonmembers, or $124 for FountainBlue Ongoing membership and admission

Registration: Please pre-register by noon on 3/12 using the PayPal link at http://www.svlifescience.com.

2 5/20/2023

Audience:      Life Science entrepreneurs, intrapreneurs and investors, no service providers please

Topic DescriptionResilient, resourceful, life science entrepreneurs are advancing their businesses, and developing international programs and relationships to better advance their technology, provide clinical research, and serve their markets. For this panel, life science entrepreneurs, intrapreneurs and investors on what's working and what's not in different international markets.

Panelists' BiosFacilitator John Bashkin, Vice President, Strategic Business DevelopmentDr. John Bashkin has 18 years of experience in technology, product, and business development for life sciences and medical devices. He has held senior business development positions at SRI International and, most recently, at Artificial Muscle, Inc.

While at SRI for seven years, Dr. Bashkin headed up business development efforts for life science and medical device technologies from across the institute as well as led his own NIH-funded research programs and served on the IP Committee for the Institute. He led contract and out-licensing negotiations for many technology and product development programs.

At Artificial Muscle, he was responsible for all corporate contract matters as well as business development for the medical industry. Prior to joining SRI, Dr. Bashkin was a senior researcher at Molecular Dynamics and Amersham, where he led the development of the first high-throughput DNA sequencing system.

He received his B.S. in Chemistry and Physics from the University of Arizona, his Ph.D. in Chemistry from Indiana University, and held post-doc positions at the University of Rochester and Johns Hopkins University. In 2000, he received his MBA from Santa Clara University.

Dr. Bashkin is a co-inventor on five issued U.S. patents and co-author on more than 20 publications.

Panelist Dr. William Goure, President and CEO, Acumen Pharmaceuticals Since May 2008, Dr. Goure has been President and CEO for Acumen Pharmaceuticals. Dr. Goure has over 20 years of domestic and international experience in the discovery, development, registration, commercial development, and commercialization of chemical and biotechnology products.

Prior to joining Acumen, Dr. Goure was Vice-President for Commercial Development for Mendel Biotechnology, a bay area company dedicated to creating value through the discovery, development and commercialization of knowledge about plant gene expression. At Mendel, Dr. Goure negotiated numerous technology collaboration and partnership agreements that generated over $29 million dollars of near term revenues.

Prior to joining Mendel, Dr. Goure worked for Monsanto Company for 17 years where he developed and commercialized Roundup Ready® soybeans, canola, and cotton. Dr. Goure was a member of the team that established Monsanto's quality traits program that led to the Renessen joint (partnership) with Cargill, and was responsible for establishing commercial launch teams in Eastern Europe, South Africa, and Southern Latin America.

3 5/20/2023

Dr. Goure has a B.S. degree in Chemistry from Fort Lewis College, Durango Colorado, and a Ph.D. degree in organic chemistry from Iowa State University. Prior to joining Monsanto, Dr. Goure was a Post-Doctoral Fellow at Colorado State University.

Panelist Taylor Kilfoil, President, CEO and Co-Founder, Inclin, Inc.

Taylor Kilfoil is the President, CEO and Co-Founder of Inclin, which provides a range of clinical, regulatory, and quality assurance services to pharmaceutical, biotechnology, and medical device companies. Taylor earned a Bachelor of Science from St. John's University.

Panelist Dr. Evgeny Zaytsev, General Partner, Helix VenturesEvgeny Zaytsev co-founded Helix Ventures in 2008 and brings eight years of venture capital and nine years of operations and research experience to the firm. Since 2001 together with Graham Crooke he managed the life sciences portfolio in two venture capital partnerships at Asset Management Company, one of the oldest venture capital firms in Silicon Valley. He was one of the key executives of the Medico-Ecological Institute, a research institute established in Russia in 1993 to study the health and environmental effects of the Soviet Union's nuclear testing program. An expert in physiology and radiation biology, he was chief scientific officer from 1994 to 2000 and during his tenure the institute became an internationally recognized research center. He is the author or co-author of 45 scientific and business publications, including six books on radiation and cancer epidemiology. From 1991 to 2000, he was also an assistant professor in physiology at the Altai State Medical University in Barnaul, Siberia.He received his M.D. (cum laude) in 1991 and his Ph.D. in physiology in 1993, both from the Altai State Medical University. He earned his M.B.A. from the Stanford Graduate School of Business in 2002. He is currently a director of several private life sciences companies. He is an Advisory Board member and past president of the American Business Association of Russian Professionals ("AmBAR").

Panelist from Morrison Foerster to be confirmed**************************************************************************************************************************

Bio2Device Group, Tuesday Morning, March 16, 2010

Topic: “Medical Device Clinical Research around the World” Speaker: Dr. Sujith Shetty, Clinical Research Manager, Micrus Endovascular Corp Date and Time: Tuesday, March 16, 2010, 8:30 – 10:30 amLocation: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)Cost: FreeParking: On street and in NOVA and library parking lots across the street.

Topic DescriptionDr. Shetty will be speaking about the challenges and opportunities of conducting clinical research in and outside the U.S. He will share insights about the need for clinical research and evidence based medicine and how it impacts industry. He will also discuss the challenges seen in working in various countries around the world. Clinical Research and its impact on a biospace company can be significant in terms of effectively presenting a novel device to the marketplace. Good Clinical results can significantly facilitate the issuance of regulatory approvals and it is also an effective tool to introduce the new product to physicians.

Speaker Bio

4 5/20/2023

Dr. Sujith Shetty is currently the Clinical Research Manager at Micrus Endovascular Corp where he is engaged in pre- and post-approval clinical research of intravascular neurologic devices. He was the Manager of Scientific Affairs at Pulmonx, and Senior Research Associate at Asthmatx, and Clinical Research Fellow at USC Keck School of Medicine. Dr. Shetty received his medical training at the Kempegowda Institute of Medical Science in Bangalore, India.***************************************************************

MX Free Webinar, Tuesday Morning, March 16, 2010

Topic: “The Medtech Marketplace in 2010”Moderated by:Sherrie Conroy, Director of Content, Medical Device BrandsTopics and Speakers:

“New Product Development & Launch Strategies - The Next Era in Medtech, ”Rebekkah Carney, MIM, Associate Vice President, MedSurg Insight, GfK Healthcare

Topic: “Transactions in the Medtech Space,” John L. Babbit, Transaction Advisory Services, Ernst & Young

Date and Time: Tuesday, March 16, 2010, 11:00 am – noon PTCost: FreeRegister https://event.on24.com/eventRegistration/EventLobbyServlet?target=registration.jsp&eventid=196562&sessionid=1&key=071AB697524B2F87A8098187C0AA5389&sourcepage=register&partnerref=promo2

Topic DescriptionIn 2009, the global economic downturn affected even the so-called recession-resistant medical device indistry. In 2010, everything from healthcare reform to reimbursement and electronic medical records will shape healthcare systems in the United States and elsewhere. This annual event offers company leaders a chance to take stock of the trends and changes that will affect their business, so that they can make the most of their strategic decisions throughout the coming year. In this FREE Webcast, “The Medtech Marketplace in 2010,” hosted by MX, industry experts provide insights into the factors driving change in some of medtech’s key sectors this year—and beyond.The Webcast will conclude with a live panel discussion moderated by Sherrie Conroy, Director of Content, Medical Device Brands 

Panelist Bios

John Babbitt is the Life Sciences Industry Sector Resident for Ernst &Young’s North America Transaction Advisory Services Practice. He has over 18 years of experience, all in the healthcare industry. John originally joined E&Y in 1995. Prior to rejoining E&Y’s TAS practice, he was CFO of a publicly traded medical technology company and was responsible for all financial and operational aspects, including capital raising and negotiating/structuring numerous collaborations and licensing arrangements. Operations experience in combination products, biologics, cellular therapies, cardiac surgery and interventional cardiology. John has transaction experience in many sectors of the life sciences industry including medical technology, biotechnology, pharmaceuticals, CROs, and CMOs. He received a BBA in accounting and an MBA in finance from the University of Miami.

Rebekkah Carney provides strategic solutions and client support for the MedSurg Insight team of GfK Healthcare, a full-service marketing research provider. In addition to supporting the market research needs of leading medical and surgical device manufacturers, she is also charged with enhancing the range of solutions available to the

5 5/20/2023

device and diagnostics industry and ensuring that the needs of her clients are matched by the skills and expertise of the research teams that support them. With 15 years of client and vendor-side experience supporting the growth of innovative medical device manufacturers, her goal is to ensure that their marketing strategy is as well designed as their products. Rebekkah is a member of the Healthcare Businesswomen’s Association (HBA) and has been a contributor to MX on building integrated market intelligence strategies. She holds a BA from Mt. Holyoke College and a master's degree in international management (MIM) from The American Graduate School of International Management.***************************************************************

NorCal BioPharmaPM, Friday Morning, March 19, 2010

The NorCal BioPharmaPM holds monthly breakfast meetings. These meetings are open to anyone who is interested in project management and works for the Pharma, Biotech, Medical Devices or Life Sciences industries  Topic: “How to Become a Great Project Manager “Speaker: Charles Follett, partner of the Stratam Group Date and Time: Friday, March 19, 2010, 8:00am – 10:00am Location: Novartis Pharmaceuticals Corporation, 150 Industrial Road, San Carlos, CA 94070Phone: (650) 622-1500Cost: Free Register at: BioPharmaPM.com, to confirm your reservation. Event Contact Info: NorCal BioPharmaPM Vice Chair , Doug Tambling ******************************************************************* Palo Alto AWIS, Monday Evening, March 22, 2010

Topic: Stem Cells and Women's HealthSpeaker: Dr. Reijo PeraDate and Time: Monday, March 22nd, 2010Schedule7:00-7:30 pm Networking and light supper7:30-7:45 pm Announcements7:45-8:45 pm Program8:45-9:00 pm DiscussionLocation: PARC Auditorium, 3333 Coyote Hill Road, Palo AltoRSVP: online http://www.acteva.com/go/pa-awis

Topic DescriptionDr. Rejio Pera will discuss her research on Stem cells andreproduction, Women’s somatic health and Women in Cancer.

In recent years, much emphasis has been placed on realizing the promise of stem cells in medicine. Yet, little focus has been placed on issues related to women’shealth. We seek to improve women’s health through stem cells.

Stem cells and reproductionIn the USA, reproductive failure carries a cost burden that exceeds $6 billion annually.Yet, research on reproductive failure, especially on the earliest stages of humanreproduction, has been excluded from federal funding. Our group explored the use ofmodern developmental genetic and biophysical means to develop novel diagnosticsand interventions based on scientific evidence. The use of assisted reproductive

6 5/20/2023

techniques to alleviate reproductive failure results in the annual culture of more than amillion embryos. Unfortunately, the vast majority of cases fail to develop properly forunknown reasons. We have sought to remedy the current state, with studies that willresult in the optimization of embryo culture and diagnosis of germ line and embryodevelopmental competence and subsequent fetal and neonatal consequences.

Women’s somatic healthCardiovascular disease has been the leading cause of death in women for decades;diabetes and autoimmune diseases disproportionately afflict women and with theextension of women’s lifespan, degenerative disorders such as urinary incontinence.Given these facts, a concerted effort to capitalize on the potential of stem cells insomatic health of women is merited.

Women and CancerSeveral cancers are most frequent or exclusive to women including breast cancer andovarian cancer. Promising potential therapies include immunologically-basedtherapies and therapies aimed at targeting cancer stem cell populations. Efforts tofocus cancer stem cell efforts on women’s cancer will be discussed.We have unprecedented opportunity to explore the unique biology of humandevelopment, including that of women, with the advances in stem cell biology

Welcome!!  You don’t need to be a member to attend.All scientists, students, and their friends are welcome.  Men too!Members and students pay $5 and non-members pay $10

**********************************************************************Bio2Device Group, Tuesday Morning, March 23, 2010

Topic: “Starting Out Right:  The Key Legal Considerations in Setting up a Life Sciences Company” Speaker: Deborah A. Marshall, Partner, Sidley Austin, LLPDate and Time: Tuesday, March 23, 2010, 8:30 – 10:30 amLocation: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)Cost: FreeParking: On street and in NOVA and library parking lots across the street.

Topic Description

Silicon Valley is frequently described as a unique ecosystem of entrepreneurs, research institutions, investors and advisors who have developed a common language and way of doing business that enables innovation and growth.  This common language is reflected in the key agreements that every company must put into place in order to effectively create, develop, protect and commercialize its technology.   Join us for a lively discussion of the legal aspects of the startup process.

Speaker BioDeborah A. Marshall, a partner with the Sidley firm, concentrates her practice on strategic business counseling for emerging growth companies and investors at all stages of development, from start-up entrepreneurs to publicly traded entities and technology-based, multinational corporations. Ms. Marshall has advised issuers, investors and investment banking firms in the internet, software, electronics, clean technology, media, entertainment, biopharmaceutical, genomics, medical device and diagnostics sectors.

7 5/20/2023

She has significant experience in venture capital financing, mergers and acquisitions, public offerings, private equity and strategic partnerships.

Ms. Marshall is a frequent speaker on issues related to venture capital, emerging growth companies, life sciences, public securities and entrepreneurship. She has been a guest lecturer on entrepreneurship at the University of California Berkeley Haas School of Business, as well as a member of the faculty of the Haas Business School’s Global Bio-Executive Program.

Ms. Marshall’s work as a corporate lawyer is highlighted in the 2007 Corporate and Finance version of The Legal 500 United States edition.

************************************************************BioScience Forum, Wednesday Evening, March 24, 2009

Topic: "Personalized Medicine: Yesterday, Today and Tomorrow. How Genomic Information has, is and will Change Healthcare" Speaker: Steve Rosenberg, Ph.D., Chief Scientific Officer, CardioDxDate and Time: Wednesday, March 23, 2010; 6:00pm - 9:00pm6:00 PM - networking 7:00 PM - dinner 8:00 PM - presentationLocation: The Clarion Hotel, 401 East Millbrae Avenue, MillbraeFull info and Registration at:http://biosf.org/

Typical Cost: $50 before 11:55 PM, Monday, March 22nd$60 on-site$35 full-time students pre-registration$45 full-time students on-site Acteva fees of $3 are added to the above prices Check website for latest informationCash or check accepted on the day of the eventParking is $2 Or you can pay with a check made out to "BioScience Forum" and sent to: BioScience Forum, 1442A Walnut Street, #308, Berkeley, CA 94709-1405 Please do not mail checks later than Thursday, March 18thIf paying with check, do not complete registration with Cvent

Topic DescriptionThe ability to decipher genomes started with viruses and bacteria and rapidly moved to eukaryotes and finally to mammals, especially Homo sapiens.  The speed at which this technology has progressed is mind-boggling, from Maxam-Gilbert sequencing in the 70s to single molecule sequencing today.  But how has this tsunami of information benefited human healthcare? Steve will discuss early examples from virology, cite current examples from oncology and cardiovascular diseases, and speculate on what the future may hold.  BiographySteve has been the Chief Scientific Officer at CardioDx, a molecular diagnostics company, focused on the application of genomic information to cardiovascular diseases, since 2006, and led the team which launched Corus CAD™, a blood based gene expression test for the assessment of coronary artery disease, in 2009.  Prior to that he spent three years at XDx, leading the team which developed Allomap™ gene expression testing for detection of rejection in heart transplant recipients.  From 1981 to 2001 Steve

8 5/20/2023

occupied positions of increasing responsibility at Chiron Corporation, where he was named one of three Chiron Fellows in the company.  He completed his PhD and post-doctoral work in biochemistry at UC Berkeley.****************************************************************

BayBio Therapeutic Breakfast Series, Thursday Morning, March 25, 2010

Topic: “Establishing and Successfully Managing Strategic Alliances”Panel Moderator:  Mike Brasseur, Vice President, Business Solutions, M Squared Consulting, Inc. - Life SciencesPanel Speakers:   Patrick Bigot, Senior Director, Head of Alliance Management, Genentech, Inc. Patrice Bruneman, Director, Strategic Alliances, Medivation Monique Nicoll , Sr. Director, Research & Discovery Alliance Management, Exelixis, Inc.Venkat Ramanan, Director, International Access Operations, Gilead Sciences, Inc.Date and Time: Thursday March 25, 2010, 8:00am – 10:00amLocation: Wells Fargo Insurance Services Inc., 305 Walnut Street, Redwood City, CA 94063Register at: http://www.baybio.org/wt/page/managing_strategic_alliancesEvent Contact Info: events@baybio.orgCost: Through March 23: $10 BayBio and ASAP members, $20 non members; On-site registration March 25: $20 BayBio and ASAP members, $40 non members

Topic Description The current economic climate, and market pressures are forcing a change in strategy for both established and emerging life sciences companies. The IPO market is gone. The VC funding is dry. Companies, seeking to deliver new treatments and cures, are forming alliances with larger organizations at a faster pace. Some are even saying that we are witnessing a fundamental change, where success will depend on a company's capacity to manage multiple relationships as part of a larger collaborative network. To be successful, companies will need to effectively develop and manage alliances, they must also learn how to remain relevant to their partners and be flexible enough to evolve with changes in the partner's strategy. Join us for a panel of expert Alliance executives to learn how to become "alliance capable" and thrive through collaborations in the new environment.

******************************************************************

San Jose Biocenter, Thursday Afternoon, March 25, 2010

Topic: How to Become a VC Magnet? A Panel & Networking ReceptionPanelists: Andrew McMillan, Ph.D. , Principal, 5AM Ventures - an early-stage VC

focused on building next-generation life science companies. Rowan Chapman , Partner, Mohr Davidow Ventures - an early stage VC

investing in innovative entrepreneurs. Wendye Robbins, MD , President & CEO, Limerick BioPharma - which

completed a Series C financing, securing $15M in new funds. Anthony Ford, Ph.D. , Founder & CSO, Afferent Pharmaceuticals - which just

received $23M in Series A financing. Mickey S. Urdea , Co-Founder, Chairman & CEO, Tethys Bioscience - which

recently closed a $25M Series D financing.

9 5/20/2023

Lead Facilitator: Scott M. Iyama, Corporate Senior Associate, Orrick, Herrington & Sutcliffe LLP - our Lead Facilitator, and a member of the Emerging Companies Group, which advises emerging companies and VC firms.

Date and Time: Thursday March 25, 2010 3:00-3:30 PM Networking and Registration 3:30-5:00 PM Expert Panel 5:00-6:30 PM Networking ReceptionLocation: Orrick, Herrington & Sutcliffe LLP, Silicon Valley Office, 1100 Marsh Road, Menlo Park, CA 94025-1015*Pre-registration closes on March 23rd at noon!*• Regular Price: $60• Partners' Network: $50 (Bio2Device Group members eligible for partner network discount; just note B2DG under affiliation)• BioCenter Members: Free (please RSVP to Aurélie)• On-site Registration: add $10 to the above This event is typically sold out, so early pre-registration is recommended to avoid disappointment on the day!Register at http://www.acteva.com/booking.cfm?bevaid=196787

Topic DescriptionEffectively raising capital is crucial for any company. Sufficient capital helps ensuring R&D, Due Diligence, Legal and Accounting services, Marketing, and improves hiring potential. In this session, a panel of VCs and CEOs will deliver the tips and tricks to realizing a successful financing process. Questions that will be raised include:» What are the steps to prepare for a financing round?» What are the strategies for attracting, securing and structuring financing deals?» Is there a valuation best practice for an emerging company in this complex environment?» When to start your financing round, and when not to? Our Panel discussions are candid, interactive and informal. We want you to walk away with the real story behind how things work so you can make it happen yourself. This Panel will be followed by a Networking Reception.************************************************************

East Bay AWIS,Thursday Evening, March 25, 2010

Topic: “Careers for Scientists in the Legal Professions”A panel discussion featuring:

Madhuri “Mani” Roy, PhD, Scientific Advisor and Patent Agent, Wilson Sonsini Goodrich and RosatiKathleen McCowin, JD, MS, Licensing Officer, Office of Technology Licensing,University of California, BerkeleyCarol Mimura, PhD, Assistant Vice Chancellor for Intellectual Property & Industry Research Alliances,University of California, Berkeley

Date and Time: Thu, March 25, 6:30pm – 8:30pmLocation: Novartis, Building X-310, 5300 Hollis Street (map)Description *************************************************

San Jose State University Biomedical Engineering Society, Tuesday, March 30, 2010

Event: Bay Area Biomedical Device Conference 2010

10 5/20/2023

Speakers: Julian Nikolchev, Founder & CEO, Pivot, Inc. Rob Abrams, Operating Partner, Sanderling Ventures Tom Bauer, M.D., Ph.D., The Cleveland Clinic Foundation Larry Eiselstein, Ph.D, P.E., Exponent, Inc. Raj Makkar, M.D., Ph.D., Cedars’ Sinai Medical Center Jeffrey Lotz, M.D., Ph.D., Professor, University of California, San Francisco

Date and Time: Tuesday, March 30, 2010, 8:00 am – 5:00 pmLocation: Engineering Auditorium at SJSUFor details and on-line registration, go to:http://www.engr.sjsu.edu/bmes/2010Conference.htmlCost:

$195 Early Registration $245 Late Registration (After 3/17/2009) $275 Walk in registration $40 SJSU Students $75 Non-SJSU Students

Event DescriptionThe Organizing Committee has identified and invited a set of outstandingspeakers who will address several areas that are critical to the biomedicaldevice industry.  There will be presentations on interventional cardiology,device explants, corrosion of implants, intervertebral disc degeneration andregeneration, appropriate selection of animal models for clinical trials,regulatory affairs and entrepreneurship pertaining to medical devices.  Thisevent will not only cover technologically significant advances in the field,but will also serve as a networking opportunity.

**********************************************************************

Free UCSC Extension Bioscience Program, Tuesday Evening, March 30, 2010

Topic: Bioscience Program Information and Q&A SessionInstructor: Michelle Ragozzino, Ph.D., Program DirectorDate and Time: Tuesday, March 30, 2010, 6:30 – 8:00 pmLocation: 2505 Augustine Drive, Santa Clara, CACost: No fee but enrollment requiredRegister at www.ucsc-extension.edu

Course Description:This free evening event is an informal discussion geared towards new or returning students interested in one or more of the Bioscience certificate programs. Led by the director of the Bioscience programs, the event begins with a short overview of the five Bioscience certificates, followed by an open-floor segment for audience questions.

***************************************************************Triple Ring Technologies, MedTech Frontiers, Wednesday Evening, April 1, 2010

Topic: “The Role of Medical Robotics in the Treatment from Cancer to Hair Transplantation”Speaker: Dr. Mohan Bodduluri, Co-Founder and VP of R&D, Restoration Robotics

11 5/20/2023

Date and Time: April 1 2010; 6:00 – 6:45 PM Refreshments 6:45 – 8:00 PM Presentation & Questions 8:00 – 9:00 PM Networking & ConsultationsLocation: Triple Ring Technologies, Inc. 39655 Eureka Drive Newark, CA 94560 (510) 592-3000Cost: Free but registration is required. Go to http://contactbeacon.com/cb/prefs/reg.php?id=33713bf7-c76e-4e4a-8d2a-32ecc8224779

Topic DescriptionThe event on April 1 will feature Dr. Mohan Bodduluri, co-founder and VP of R&D at Restoration Robotics. Dr. Bodduluri was previously VP of R&D at Accuray, where he helped develop the Cyberknife system. His presentation will focus on various technologies, such as image processing, machine vision, and robotics, that have to come together to be effective in the highly regulated field of medical devices.In particular, the talk will focus on the two companies the speaker has been involved in, Restoration Robotics and Accuray.*****************************************************************

FountainBlue, Friday Morning, April 2, 2010Topic:” FountainBlue's Funding Road Trip: Perfecting Your Pitch to Investors”Speaker: Bill Joos, principal of "Go To Market ConsultingDate and Time: Friday, April 2, 8:30 a.m. - 1:00 p.m.8:30    Registration and Networking, in the Cooley Café 9:00    Bill Joos: Perfecting Your Pitch to Investors, in the Cooley Café 10:30  Morning Break 10:45  Pitch Practice Sessions - 15 mins a team1:00   Optional Pitch Debrief Meeting 1:30   Adjourn. Please note that we have the room until 1:45 p.m. and we welcome you to stay to network with fellow entrepreneurs.Location: Cooley Godward Kronish LLP, 3175 Hanover, Palo AltoAudience: Early-Stage, Funding-Bound Clean Energy, High Tech and Life Science Entrepreneurs and Intrapreneurs, who have attended our October and/or our November workshops

Cost for 1 or 2 Entrepreneurs: $83 for FountainBlue members, $93 for Partners, $103 GeneralOn-Site for members is $103 and $124 and for non-members.

Registration: Please pre-register by noon on 3/31 using the PayPal link at http://www.fountainblue.biz/fundingroadtrip.html.

Topic DescriptionFountainBlue cordially invites high tech, life science and clean energy entrepreneurs to the second funding preparation workshop entitled 'Perfecting Your Pitch to Investors'. This hands-on workshop, which follows the first workshop entitled 'Your Company's Value Proposition', will take entrepreneurs through the process of creating and delivering a compelling elevator pitch, a one-page executive summary and a 13-15 slide company overview presentation. Attendance at one of the two workshops in the series is a pre-requisite to attending our third and final workshop in the series, 'Your Meeting with Investors', which features feedback from active investors. For this workshop, working in partnership with fellow entrepreneurs in similar, non-competing spaces, participating entrepreneurs will have the opportunity to learn best practices and immediately apply these learnings to their own companies. Whether you

12 5/20/2023

are a serial entrepreneur, or someone who may be considering a future opportunity, you are sure to benefit from the information presented, the connections made and the peer-to-peer knowledge shared.

Speaker BioBill Joos is the principal of "Go To Market Consulting", based in Palo Alto, CA. He works with early stage startups, venture capital firms and their portfolio clients. Most recently he spent 6 years as the VP of Entrepreneur Development at Garage Technology Ventures, an early stage venture capital firm that he co-founded along with Guy Kawasaki. His reputation at Garage was that he provided their clients with effective, hands-on, action-oriented strategic and tactical mentoring and coaching. Bill has worked with literally hundreds of early-to-mid stage startups and helped them polish and clarify their messages and refine their fund-raising and customer presentations; but his contributions to them extended well beyond being a "Pitch Doctor". He has mentored and coached them in go to market strategies, revenue and pricing optimization, business alliances, business development, partnerships, and marketing. Over 15,000 entrepreneurs worldwide have attended conferences where Bill has been a featured keynote speaker on various entrepreneurial topics. He has held sales and marketing positions with a variety of companies, including IBM and as a VP of the software division of Apple Computer.

*******************************************************************

Bio2Device Group, Tuesday Morning, April 6, 2010

Topic: Self-guided SurgerySpeaker: John Black, Ph.D., VP, Imaging, Avinger Inc.Date and Time: Tuesday, March 16, 2010, 8:30 – 10:30 amLocation: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)Cost: FreeParking: On street and in NOVA and library parking lots across the street. Topic DescriptionThe introduction of the laser as a therapeutic surgical tool in the 1960's has had a profound effect on certain fields of medicine, particularly in ophthalmology and more recently in minimally invasive surgical disciplines such as urology. The use of laser-based optical diagnostic tools, both as stand-alone devices and coupled to other instruments has recently started to blossom as many of the advances in electronics, computing and optical telecommunications of the last decade make their way into the biophotonics field. The enabling features of light-based diagnostics include the ability to use fiber-optics, sometimes with outer diameters as small as 50 microns as conduits for information, the extremely high intrinsic bandwidths and signal-to-noise of optical systems, and the possibility of using both the spectral and coherence properties of laser light to yield simultaneously both functional (molecular level) and structural (tissue organization) information.John will present a tour of how optical techniques available today can be used to sense temperature, pH, and force, and show how the optical analog of ultrasound, Optical Coherence Tomography, is being used to equip surgical instruments with the ability to allow the physician to image the tissue they are interacting with and to make a treatment decision in real time, with 10-micron precision, all with minimal mechanical and cost impact on the surgical tool. Examples from thermal coagulation (ablation) and intravascular plaque excision will be discussed.

13 5/20/2023

Speaker Bio:John Black has 16 years of experience in the medical, commercial and research segments of the photonics industry. At Avinger, he leads the engineering effort in the development of image-guided catheters for the treatment of peripheral and coronary artery disease. Prior to Avinger, he led the optical engineering team at FoxHollow Technologies in the successful development of the first-in-man intravascular real-time image-guided plaque excision catheter (Nighthawk™). http://www.medicalnewstoday.com/articles/51482.php.At Coherent Medical he was the manager of the Laser / Tissue Engineering group spearheading the development of flagship surgical, ophthalmic and dermatologic applications of lasers. While at Coherent he pioneered a new treatment of cutaneous vascular lesions which led to the development of the Cynosure Cynergy™ Vascular Workstation (unfortunately not the Coherent Cynergy Vascular Workstation). Also at Coherent he co-discovered the first laser-activated intravascular blood-pool MRI contrast agent. After Coherent he joined Lightwave Electronics (now JDSU, Inc.) working initially on advanced fiber lasers for RGB projection systems in consumer electronics ( http://www.sony.net/Products/SC-HP/cx_news/vol40/sideview.html), and subsequently on the laser design for the industry-leading Xcyte™ mode-locked ultraviolet laser for flow cytometry. John has a B.Sc. in Chemistry with First Class Honors and a Ph.D. in Physical Chemistry from the University of Nottingham. He received the T.J. King Memorial Prize for undergraduate physical chemistry research and an SERC / NATO Research Fellowship to do post-doctoral research in photochemistry at Stanford University. He was also a post-doctoral research fellow at Columbia University developing new lasers for molecular spectroscopy and reaction dynamics. He has lectured widely both in the US and abroad on laser spectroscopy and applications in medicine, and has several well-cited publications in these areas. John has 4 issued patents and several pending applications in the fields of laser development, trans-dermal cardiac output monitoring, optical diagnostics, and medical devices. He is a Senior Member of the IEEE, and a member of OSA, APS, SPIE and Sigma Xi. He has also been a Guest Lecturer at the University of Arizona Biomedical Engineering Program, and is a peer-reviewer for several high-impact journals including Optics Express, Optics Communications, Lasers in Surgery and Medicine and the Springer “Series in Optical Sciences” books.

********************************************************************

Stanford Center for Law and the Biosciences, Friday, April 9, 2010

Topic: “Drug Development and International Access”Speakers Include:

• Gregg Alton, Executive Vice President, Corporate and Medical Affairs at Gilead • Tom Bollyky, Fellow at the Center for Global Development • Robert Chess, Chairman, Nektar Therapeutics; Board member and initial Chairman, Bio Ventures for Global Health• Richard Chin, CEO of OneWorld Health• Joe Damond, Vice President of Government Relations at Pfizer• Charlie Kinzig, Vice President of Corporate Intellectual Property at GlaxoSmithKline • Carol Mimura, Assistant Vice Chancellor, UC Berkeley Intellectual Property & Industry Research Alliances• Jenik Radon, Professor at Columbia University's School of International and Public Affairs• Hannu Wager, Counselor in the IP Division of the WTO, and Secretary of the WTO TRIPS Council

14 5/20/2023

Date and Time: Friday, April 9, 2010, 9:00 am – 2:00 pmLocation: Stanford Law SchoolCost: Free This event is free and open to the public. For more information, please contact Kelly Lowenberg at klowenberg@law.stanford.edu or visit the event website. Register at http://www.stanford.edu/dept/law/forms/DrugDev.fbTopic DescriptionMany life-threatening diseases disproportionally affect people in low-income and middle-income countries. Even when treatments exist, many people are unable to afford essential medicines needed for survival. While patent protection for new medicines is necessary to incentivize drug research and development, in developing countries, these patents prevent price-lowering competition.Professor John Barton, a member of the Stanford Law School faculty for 40 years, devoted the latter part of his distinguished career to increasing access to medicine while continuing to provide incentives for drug development. In 2008, Professor John Barton and Pfizer CEO Jeff Kindler proposed a new international framework on drug pricing, favoring IP exemption for the poorest countries, an international drug approval process, divided markets in middle-income countries, and trade agreements among developed countries to ensure policies recognize and reward innovation. In tribute to Professor Barton's work and his dedication to increasing access to medicine, this conference aims to discuss some of the innovative new business models and intellectual property strategies, including Professor Barton's proposal, which will make it possible for more patients to have access to life-saving medicines. Speakers will discuss business strategies to incentivize research and development, models to reduce the cost of drug development, and intellectual property, regulatory, and pricing structures effecting access to medicine.

********************************************************************

Bio2Device Group, Tuesday Evening, April 13, 2010

Topic: “A Serial Entrepreneur's Journey- How a Physicist became a Leading Device Innovator” Speaker: Hira Thapliyal, Ph.D., President and CEO, VytronUS, Inc.Date and Time: 4/13/2010, 6:00 pm Location: TIPS, 1000 Elwell Ct., Suite 150, Palo Alto, CA Cost: $6 - Students/In-transition - Members only $11 - Early-bird Registration - Members only $20 - Late Registration and Non-Members $25 - Walk-ins Register online at www.bio2devicegroup.org

Topic DescriptionHira Thapliyal will discuss his journey from a physicist to a leading serial entrepreneur in Silicon Valley/USA. He will discuss the highs and lows, and some lessons he has learned along the way. Along his successful career path you will see familiar companies that he has lead and/or founded such as DVI, CVIS, Arthrocare, Tescient, MicroBionics, and VytronUS.

Speaker BioDr. Hira Thapliyal, Ph.D., got started in the medical device industry while developing a cauterizing, glass scalpel. A cardiovascular industry veteran, who played a critical role in the founding of companies such as atherectomy pioneer DVI (Devices for Vascular

15 5/20/2023

Intervention Inc.), and intravascular ultrasound leader CVIS (Cardiovascular Imaging Systems, now part of Boston Scientific Corp.). Three years later he became CEO of MicroBionics, Inc. Thapliyal then founded a new company in April 1993 called ArthroCare Corporation, which used coblation technology to facilitate arthroscopic joint surgery. Dr. Thapliyal served as the company's initial president and chief executive officer. Hira then co-founded and was CEO of Tescient, Inc. Hira is currently the President & CEO of VytronUS, Inc. VytronUS is developing products in cardiovascular field. Hira is currently a member of the Board of Directors for Apsara Medical, Inc., Intact Medical, Inc., and PAVAD Medical, Inc. He is also the Special Partner of MedVenture Associates IV. Dr. Thapliyal is also an Advisory Board Member to the Department of BioEngineering at University of California, Berkeley and Materials Science and Engineering at Cornell University.Dr. Hira Thapliyal earned his B.S. in electrical engineering from Washington State University, followed by an M.S. in electrical engineering from the University of Idaho and a Ph.D. in materials science and engineering from Cornell University.

**********************************************************************Bioscience Business and Marketing Essentials, Thursday and Friday, April 15-16, 2010

2-Day Intensive Course: Bioscience Business and Marketing Essentials, Thursday and Friday, April 15-16, 2010 with 2 months to complete projectLead Instructor: Audrey S. Erbes, Ph.D., Principal, Erbes & Associates and www.audreysnetwork.comExpert Guest Speakers: Donald Holsten, Pharm. D., Regulatory Consultant and Educator Bev Hudson, MBA, General Manager, Clinical Research Services, MedPoint

Communications, Inc Julie Tompkins, MBA, Sr. Vice President, Timely Data Resources (TDR)Please see www.ucsc-extension.edu/biobusiness for complete biographiesDate & Time: April 15-15, 2010, Thursday and Friday, 8:30am-5pmLocation: UCSC Extension in Silicon Valley, 2505 Augustine Drive, Santa Clara, CA 95053Fee: $750; $675 through April 1

Topic DescriptionThe bioscience industry is like no other. Lengthy timelines and unique financial, legal, regulatory, social and political challenges impose constraints that impact every aspect of the business. This course helps participants gain: a practical understanding of the bioscience industry landscape, key business drivers and challenges; insight into the critical roles that business and marketing disciplines play at all stages of a bioscience company's development; and hands-on experience implementing important bioscience business processes that are essential to success within the industry. Two days of intensive classroom are followed by 2 months to complete individual project with guidance of instruction and access to research resources.  For more information: See www.ucsc-extension.edu/biobusiness.

Instructor BioAudrey Erbes, Ph.D., Principal of Erbes & Associates and www.audreysnetwork.com, is a marketing consultant with more than 30 years of managerial experience in marketing and business development in the biotech and pharmaceutical industries. She was Executive Vice President and cofounder of Kowa Research Institute, a biopharmaceutical licensing and investment subsidiary of Kowa Company Ltd., Japan and before that held management positions at Syntex Corp. in market research, product management, strategic marketing and planning, and business development in the U.S. and abroad.

16 5/20/2023

**********************************************************************

BayBio NEST Venture Spotlight, Thursday Morning, April 15, 2010

Topic: “A Tailor Made Approach: Personalized Medicine”Panel Moderator: Jeff Peterson, CEO, Target DiscoveryPanel Speakers: Bill Gerber, Bay City CapitalDate and Time: April 15th, 2010, 8:00 – 10:00 amLocation: Latham & Watkins, Menlo Park Campus, 140 Scott Dr., Menlo Park, CA 94025Cost: Early Bird Registration through March 13th:$19.00;On-Site Registration, March 15th:$29.00Register at http://www.acteva.com/booking.cfm?bevaid=195773

(If you are an employee of a Sponsor company, please contactProgram Manager, Jessica Knowles to obtain your complimentary registration.)

Topic DescriptionThe crisis of health care economics is now frighteningly familiar to us all, driven by advancing technology often coupled with increasing cost. Personalized Medicine is our greatest hope for remediation of this rising economic tsunami. Decades of advances in molecular biology are now delivering important new diagnostics for Personalized Medicine (PMDx) to determine the patient's response, resistance or toxicity risk before or during treatment, in order to optimize the selection of medical treatments from amongst the alternative options. Patients benefit enormously by not wasting valuable months of treatment time and not undergoing the side effects and physical insult of ineffective or toxic treatments like chemotherapy in cancer.

The BayBioNEST Venture Spotlight Series is a unique forum that allows investors to speak directly to entrepreneurs in a reverse pitch format. Investors and experts have a platform to discuss their current interests, target markets, therapies and technologies, as well as the maturation level of investment targets. The Venture Spotlight Series is a breakfast panel discussion with time for Q&A and networking.

******************************************************************

Bio2Device Group, Tuesday Morning, April 20, 2010

Topic: tbaSpeaker: David DeNolaDate and Time: Tuesday, April 20, 2010, 8:30 – 10:30 amLocation: Sunnyvale City Council Chambers, 456 W. Olive, Sunnyvale, CA (across the street from Sunnyvale Public Library)Cost: FreeParking: On street and in NOVA and library parking lots across the street.

************************************************************

BioScience Forum, Wednesday Evening, April 21, 2010

Topic: TBA Speaker: Jean Deleage, Ph.D., Founding Partner and Managing Director, Alta Partners

17 5/20/2023

Date and Time: April 21st, 2010

Date and Time: Wednesday, April 21, 2010; 6:00pm - 9:00pm6:00 PM - networking 7:00 PM - dinner 8:00 PM - presentationLocation: The Clarion Hotel, 401 East Millbrae Avenue, MillbraeFull info and Registration at:http://biosf.org/

Typical Cost: $50 before 11:55 PM, Monday, April 19th$60 on-site$35 full-time students pre-registration$45 full-time students on-site Acteva fees of $3 are added to the above prices Check website for latest informationCash or check accepted on the day of the eventParking is $2 Or you can pay with a check made out to "BioScience Forum" and sent to: BioScience Forum, 1442A Walnut Street, #308, Berkeley, CA 94709-1405 Please do not mail checks later than Thursday, April 15thIf paying with check, do not complete registration with Cvent**********************************************************************

San Jose Biocenter, Thursday All-Day, April 22, 2010

Topic: “Meet with… Amgen” Date and Time: Thursday, April 22, 2010 Agenda9:00 AM - 9:30 AM Registration &

Networking 9:30 AM - 10:30 AM Presentation & Q&A 10:40 AM - 11:30 AM BioCenter Tour11:30 AM - 12:30 PM Lunch & Networking12:30 PM - 5:00 PM One-on-one Meetings One-on-one Meeting Application & Costs• Application fee: FREE• Registration for one company representative:         o $175 Regular         o $150 Partners’ Network • Registration for two company representatives:         o $250 Regular         o $215 Partners’ Network• Registration for three company representatives:         o $300 Regular         o $255 Partners’ Network• Registration for four company representatives and above:         o add $40 [or $30 for Partners’ Network] per attendee• BioCenter Residents and Affiliates: Free (Bio2Device Group members eligible for partner network discount; just note B2DG under affiliation)

Presentation & Q&A Costs**• Regular Price: $40

18 5/20/2023

• Partners' Network: $30• BioCenter Members: Free (please RSVP to Aurélie)**Includes: Presentation & Q&A session ONLY. Seating is limited for this event, so early pre-registration is recommended to avoid disappointment! Additionally, there will be no on-site registrations.

Topic DescriptionEmerging companies find it increasingly difficult to reach the right person when seeking funding and/or partners. Through the “Meet with…” Series, we provide emerging companies with greater access to partnering and/or financing opportunities. In this session, Directors from Amgen will talk to potential licensees to first explain what they are looking for in a company. After the presentation, each pre-approved attendee* will be granted a private meeting with a Director from Amgen.

*Registrations to one-on-one meetings are subject to approval of application. To apply, please send your Executive Summary by April 4, 2010 to Aurélie at aurelie@sjbiocenter.com. The Review Board, composed of the BioCenter management team, sponsors, partners and mentors, will then meet to consider your application. You will be notified on April 8, 2010 if your application is accepted or rejected. Registration must be completed upon approval to secure your meeting slot.

***************************************************************BayBio Institute NEST,

Topic: Technology Showcase at SRIDate and Time: April 29th, 2010, 5:30-7:30pmLocation: SRI International, 333 Ravenswood Avenue, Menlo Park CA 94025Cost: Early Bird Registration through April 28th - $29; On-Site Registration, April 29th - $39Register at http://www.acteva.com/booking.cfm?bevaid=196082

Topic DescriptionBayBioNEST invites you to join us for the first of the 2010 Technology Showcases at SRI International. The NEST Tech Showcase allows the life sciences community to get a sneak peak at the science within often before it is published or patented and is also a great opportunity for the industry community to network with scientists, entrepreneurs and with each other.SRI International is an independent nonprofit research /development organization in existence over 60 years, whose discoveries, patents, and inventions have touched people's lives around the world!SRI's Biosciences Division provides complete discovery and preclinical development capabilities to take drugs and biologics from Idea to IND®. Our integrated program offers the scientific, technical, and regulatory expertise needed to expedite the process. We provide target identification, lead discovery/optimization, vaccine development, neuropharmacology research in sleep and pain, microbiology, efficacy models, comprehensive toxicology, PK/ADME, formulation, analytical chemistry, cGMP manufacturing, QA, IND preparation and government grant teaming services. In its CRO business, SRI has helped its clients, partners, and the Government advance well over 100 drugs into patient testing. SRI is also working to create the next generation of

19 5/20/2023

technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.*********************************************************************Bioscience Business Development: Building Value, Thursday and Friday, June 24-25, 2010

Intensive Course: Bioscience Business Development: Building Value, Thursday and Friday, June 24-25, 2010 (2 days of classroom and 2 months to complete project guided by instructor)Instructors: Audrey S. Erbes, Ph.D., Principal, Erbes & Associates and www.audreysnetwork.comand and Gilbert R. Mintz, Ph.D., President of GRM AssociatesExpert Guest Speakers: Harold (Hal) Etterman, MBA, Business Strategist Carolyn Feamster, MBA, VP, Business Strategy & Analysis Ginger R. Dreger, M.S., J.D., Partner, Arnold & Porter LLP Tom Gutshall, Chairman & Co-Founder of Cepheid Michael G. McCully, M.S., Director, Recombinant Capital Please see www.ucsc-extension.edu/biobizdev for detailsDate & Time: June 24-25, 2010, Thursday and Friday, 8:30am-5pmLocation: UCSC Extension in Silicon Valley, 2505 Augustine Drive, Santa Clara, CA 95053Fee: $795; $715.50 through June 10

Topic DescriptionUCSC Extension in Silicon Valley presents a two-day intensive course that brings the breadth of the Bay Area’s biobusiness development expertise to our Cupertino classroom. Whether financing start-up activities, trying to keep pace with the current burn rate, or moving a product into the marketplace, bioscience companies, both large and small, have a critical need for business development at every stage of their evolution. Learn the key roles that business development and licensing play in the commercialization of a new product and the development of a successful bioscience company. Santa Clara, CA. For more information, see www.ucsc-extension.edu/biobizdev

Instructor BiosAudrey Erbes, Ph.D., Principal, Erbes & Associates and www.audreysnetwork.com has more than 30 years of marketing experience in the biotech and pharmaceutical industries, of which 25 years was in corporate management at Kowa Research Institute and Syntex Corporation.Gilbert R. Mintz, Ph.D., President of GRM Associates, a biotechnology consulting firm with expertise in business development, licensing and strategic planning.

20 5/20/2023